Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Effect of KA-EX Supplementation on Recovery Parameters in High-Level Young Football Players

NCT07824752 · tracked via the Priya Life Science Italy tracker
Sponsor
Antonio Molina Lopez
Phase
Not applicable
Started
2026-09-05
Last updated
2026-09-17

Condition(s) studied

SportMuscle FatigueRecovery of Function (G11.427.698.620)Athletic PerformanceSleep Quality

Investigational drug(s) / intervention(s)

KA-EXExperimental: KA-EX Supplement

KA-EX: Powder sachet to be dissolved in water. Contains a patented complex of amino acids, electrolytes, and carbohydrates designed to normalize cortisol and support recovery.

Experimental: KA-EX Supplement: Powder sachet with identical organoleptic characteristics but without the active recovery ingredients of KA-EX.

Study summary

The purpose of this study is to evaluate the effects of KA-EX supplementation on recovery parameters in elite young football players. Athletes from the Udine Primavera team will be randomly assigned to receive either the KA-EX supplement or a sensory-matched placebo immediately following their training sessions for a period of two months.

The researchers will monitor heart rate variability (HRV) and sleep quality using Garmin wearable devices, and assess changes in body composition using Dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA). The goal of the study is to determine if post-training KA-EX administration improves physiological recovery, sleep quality, and physical readiness in high-performance athletes during a competitive season.

Eligibility

Sex
MALE
Min age
17 Years
Max age
20 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Membership of the Udine Primavera team at the time of the study. Regular participation in the training programme during the intervention period (September). Provision of written informed consent to participate in the study. Willingness to use a Garmin wearable device for continuous monitoring of recovery variables. Exclusion Criteria: * Presence of any injury or medical condition that limits normal participation in team training sessions. Use of any other recovery supplements or ergogenic aids outside of the study protocol during the intervention period. Failure to comply with the daily supplementation protocol or the scheduled assessment sessions (DEXA/BIA).

Primary outcome measure(s)

  • Change from Baseline in Heart Rate Variability (rMSSD) — Baseline and daily for 8 weeks.
    Autonomic recovery assessed as Root Mean Square of Successive Differences (rMSSD) during nocturnal sleep via Garmin wearable devices. Higher values indicate better parasympathetic recovery.

Trial sites (1)

FacilityCityRegionStatus
Stadio BlueEnergy Udine Friuli Venecia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07824752 on ClinicalTrials.gov ↗ ← All trials in Italy